Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Yellow Dock root tincture
190606000BCTJA0
|
Proprietary compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Yellow fever vacc (live) inj 0.5ml vials
1404000U0AAAAAA
|
Yellow Fever Vac | Yellow fever | Immunological Products and Vaccines | No data available |
|
Yellow Jasmine root tincture
190606000BCUJA0
|
Proprietary compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Yervoy 200mg/40ml concentrate for inf vials
0801050BCBBABAB
|
Yervoy | Ipilimumab | Malignant Disease and Immunosuppression | No data available |
|
Yervoy 50mg/10ml concentrate for solution for infusion vials
0801050BCBBAAAA
|
Yervoy | Ipilimumab | Malignant Disease and Immunosuppression | No data available |
|
Yimmugo 10g/100ml solution for infusion vials
1405010A0CIAABQ
|
Yimmugo | Normal immunoglobulin (Gamma globulin) | Immunological Products and Vaccines | No data available |
|
Yimmugo 20g/200ml solution for infusion vials
1405010A0CIABBR
|
Yimmugo | Normal immunoglobulin (Gamma globulin) | Immunological Products and Vaccines | No data available |
|
Yimmugo 5g/50ml solution for infusion vials
1405010A0CIACBP
|
Yimmugo | Normal immunoglobulin (Gamma globulin) | Immunological Products and Vaccines | No data available |
|
Yondelis 0.25mg pdr for concentrate for inf vials
0801050AVBBAAAA
|
Yondelis | Trabectedin | Malignant Disease and Immunosuppression | No data available |
|
Yondelis 1mg pdr for concentrate for inf vials
0801050AVBBABAB
|
Yondelis | Trabectedin | Malignant Disease and Immunosuppression | No data available |
|
YourNAC 600mg capsules
0307000C0BKAAAK
|
YourNAC | Acetylcysteine | Respiratory System | No data available |
|
YourNAC 600mg tablets
0307000C0BKABAM
|
YourNAC | Acetylcysteine | Respiratory System | No data available |
|
YPV Vitamin D3 1,000unit tablets
0906040G0EHAABG
|
YPV Vitamin D3 | Colecalciferol | Nutrition and Blood | No data available |
|
YPV Vitamin D3 20,000unit tablets
0906040G0EHABCR
|
YPV Vitamin D3 | Colecalciferol | Nutrition and Blood | No data available |
|
YPV Vitamin D3 4,000unit tablets
0906040G0EHACEE
|
YPV Vitamin D3 | Colecalciferol | Nutrition and Blood | No data available |
|
YPV Vitamin D3 400unit tablets
0906040G0EHADEL
|
YPV Vitamin D3 | Colecalciferol | Nutrition and Blood | No data available |
|
YPV Vitamin D3 800unit tablets
0906040G0EHAECS
|
YPV Vitamin D3 | Colecalciferol | Nutrition and Blood | No data available |
|
Yselty 100mg tablets
0607020Y0BBAAAB
|
Yselty | Linzagolix | Endocrine System | No data available |
|
Yselty 200mg tablets
0607020Y0BBABAC
|
Yselty | Linzagolix | Endocrine System | No data available |
|
Yuflyma 20mg/0.2ml inj pre-filled syringes
1001030S0BHAEAF
|
Yuflyma | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Yuflyma 40mg/0.4ml inj pre-filled syringes
1001030S0BHABAE
|
Yuflyma | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Yuflyma 40mg/0.4ml solution for injection pre-filled pens
1001030S0BHAAAD
|
Yuflyma | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Yuflyma 80mg/0.8ml inj pre-filled syringes
1001030S0BHADAG
|
Yuflyma | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Yuflyma 80mg/0.8ml solution for injection pre-filled pens
1001030S0BHACAH
|
Yuflyma | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Yutopar 10mg tablets
0701030S0BBAAAC
|
Yutopar | Ritodrine hydrochloride | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.